← Human Trials & Peer-Reviewed Studies
Neuroendocrine regulation of growth hormone and androgen axes by selective estrogen receptor modulators in healthy men.
Plain-language guide to PMID 20843951 (2010): open-label randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
Key Facts
- PMID
- 20843951
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Birzniece V et al. (4 authors)
- DOI
- 10.1210/jc.2010-1477
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.
The aim was to compare the impact of raloxifene and tamoxifen on GH-IGF-I and gonadal axes in healthy men.
Why It Was Studied
In men, the stimulation of GH and inhibition of LH secretion by testosterone requires aromatization to estradiol.
Tamoxifen, a selective estrogen receptor modulator (SERM), possesses central estrogen antagonistic effect but peripheral hepatic agonist effect, lowering IGF-I.
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, men only.
How the Study Was Run
The design is described as randomized, open-label and crossover.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Being open-label, the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study did not mask who received what.
Each person switched between Exogenous HGH, sermorelin & older GHRPs (why they're passed over) and the comparison at some point, usually with a gap in between.
The researchers conducted a randomized, open-label crossover study.
What Was Measured
In men, the stimulation of GH and inhibition of LH secretion by testosterone requires aromatization to estradiol.
PubMed files the paper under topics including Androgens, Arginine, Follicle Stimulating Hormone, Growth Hormone, Insulin-Like Growth Factor I, Luteinizing Hormone and Raloxifene Hydrochloride.
What This Means in Plain Language
The paper is a randomized, open-label and crossover study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2010 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.